Finally, we characterized the prognostic impact of PATZ1 expression first in our local cases of GBM, finding a significant worse outcome in patients showing absent or low levels of PATZ1 (< 10% positive cells), suggesting it may be used as a prognostic marker. The gene discussed is PATZ1; the disease is glioblastoma.